Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Status:
Recruiting
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral
activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical
effect on patients with COVID-19 never been tested.
In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding
among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.